These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 24043152)

  • 21. Aspirin resistance: myth or major problem?
    Grove EL; Hvas AM; Kristensen SD
    Scand J Clin Lab Invest; 2008; 68(4):257-9. PubMed ID: 18612918
    [No Abstract]   [Full Text] [Related]  

  • 22. The aspirin resistance controversy: clinical entity or platelet heterogeneity?
    Freedman JE
    Circulation; 2006 Jun; 113(25):2865-7. PubMed ID: 16801473
    [No Abstract]   [Full Text] [Related]  

  • 23. Terms and conditions: semantic complexity and aspirin resistance.
    Hennekens CH; Schror K; Weisman S; FitzGerald GA
    Circulation; 2004 Sep; 110(12):1706-8. PubMed ID: 15381661
    [No Abstract]   [Full Text] [Related]  

  • 24. Clinical pharmacology of cyclooxygenase inhibition and pharmacodynamic interaction with aspirin by floctafenine in Thai healthy subjects.
    Maenthaisong R; Tacconelli S; Sritara P; Del Boccio P; Di Francesco L; Sacchetta P; Archararit N; Aryurachai K; Patrignani P; Suthisisang C
    Int J Immunopathol Pharmacol; 2013; 26(2):403-17. PubMed ID: 23755755
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An evaluation of cyclooxygenase-1 inhibition before coronary artery surgery: aggregometry versus patient self-reporting.
    Rahe-Meyer N; Winterhalter M; Hartmann J; Pattison A; Hecker H; Calatzis A; Solomon C
    Anesth Analg; 2008 Dec; 107(6):1791-7. PubMed ID: 19020119
    [TBL] [Abstract][Full Text] [Related]  

  • 26. No case of COX-1-related aspirin resistance found in 289 patients with symptoms of stable CHD remitted for coronary angiography.
    Meen O; Brosstad F; Khiabani H; Gjertsen E; Lauritsen ME; Pedersen TM; Bjørnsen S; Schjelderup NM; Ameln W; Ng EC; Wettergreen M; Siddique SP; Erikssen G
    Scand J Clin Lab Invest; 2008; 68(3):185-91. PubMed ID: 17934975
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Frequency, risk factors, prognosis, and genetic polymorphism of the cyclooxygenase-1 gene for aspirin resistance in elderly Chinese patients with cardiovascular disease.
    Fan L; Cao J; Liu L; Li X; Hu G; Hu Y; Zhu B
    Gerontology; 2013; 59(2):122-31. PubMed ID: 23038044
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Aspirin resistance: position paper of the working group on aspirin resistance of the international society on thrombosis and haemostasis].
    Boskholov BP
    Kardiologiia; 2005; 45(7):75-6. PubMed ID: 16091668
    [No Abstract]   [Full Text] [Related]  

  • 29. Aspirin resistance is not a common biochemical phenotype explained by unblocked cyclooxygenase-1 activity.
    Hillarp A; Lethagen S; Mattiasson I
    J Thromb Haemost; 2003 Jan; 1(1):196-7. PubMed ID: 12871563
    [No Abstract]   [Full Text] [Related]  

  • 30. Aspirin resistance in the era of personalized medicine: Should we not take it personally?
    Naimo PS; McGiffin D; Konstantinov IE
    J Thorac Cardiovasc Surg; 2015 Dec; 150(6):e99-100. PubMed ID: 26463652
    [No Abstract]   [Full Text] [Related]  

  • 31. [Acetylsalicylic acid resistance--clinical diagnosis with unclear mechanism].
    Hillarp A
    Lakartidningen; 2004 Nov; 101(45):3504-6, 3508-9. PubMed ID: 15575422
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis.
    Schrör K
    Semin Thromb Hemost; 1997; 23(4):349-56. PubMed ID: 9263351
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The assessment of aspirin resistance by using light transmission and multiple electrode aggregometry.
    Ulehlova J; Slavik L; Krcova V; Hutyra M; Galuszka J; Indrak K
    Int J Lab Hematol; 2011 Jun; 33(3):305-9. PubMed ID: 21219589
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Aspirin resistance--pharmacological mechanisms and clinical implications].
    Olszanecka A; Olszanecki R; Korbut R; Kawecka-Jaszcz K
    Kardiol Pol; 2005 Jan; 62(1):87-92. PubMed ID: 15815792
    [No Abstract]   [Full Text] [Related]  

  • 35. Genetic polymorphisms of HO-1 and COX-1 are associated with aspirin resistance defined by light transmittance aggregation in Chinese Han patients.
    Li XL; Cao J; Fan L; Wang Q; Ye L; Cui CP; Wang YZ; Liu L; Li B; Wu RJ; Zhou FC; Zhang JH
    Clin Appl Thromb Hemost; 2013 Sep; 19(5):513-21. PubMed ID: 22609818
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optical aggregometry and aspirin resistance.
    Feher G; Pusch G; Szapary L
    Acta Neurol Scand; 2009 Feb; 119(2):139; author reply 140. PubMed ID: 18647274
    [No Abstract]   [Full Text] [Related]  

  • 37. Gallic acid, a dietary polyphenolic component, blunts the inhibition of platelet COX-1 by aspirin: preliminary in-vitro findings.
    Crescente M; Cerletti C; de Gaetano G
    Thromb Haemost; 2007 Jun; 97(6):1054-6. PubMed ID: 17549313
    [No Abstract]   [Full Text] [Related]  

  • 38. And, more on: assessing aspirin responsiveness using the verify now aspirin assay.
    Sarode R; Frenkel E
    Thromb Res; 2008; 121(4):587-8. PubMed ID: 17553551
    [No Abstract]   [Full Text] [Related]  

  • 39. Lumiracoxib does not affect the ex vivo antiplatelet aggregation activity of low-dose aspirin in healthy subjects.
    Jermany J; Branson J; Schmouder R; Guillaume M; Rordorf C
    J Clin Pharmacol; 2005 Oct; 45(10):1172-8. PubMed ID: 16172182
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers.
    Greenberg HE; Gottesdiener K; Huntington M; Wong P; Larson P; Wildonger L; Gillen L; Dorval E; Waldman SA
    J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1509-15. PubMed ID: 11185674
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.